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Objective: To estimate the impact of the low-dose anticancer drugs (ACD) with the different mechanisms of action and human interferon 
(IFN) alpha 2b on the biological properties, immunophenotypic and cytogenetic characteristics of colon cancer cells in vitro. Materials 
and Methods: The study was performed on human colon cancer cell lines COLO 205, HT-29 and 3C-P treated with ACD and IFN 
in subtoxic concentrations. Expression of CD44, N-cadherin, vimentin, β-catenin, ERCC1 and Slug was assessed by immunocyto-
chemical method. Using cytogenetic analysis, the numbers of mitoses, cells with micronuclei, apoptotic cells and cells with nuclear protru-
sions were studied. Results: The prolonged exposure (up to 30 days) of colon cancer cells to low-dose ACD (0.2–0.5 µg/ml cisplatin and 
0.1–0.2 µg/ml irinotecan) in combination with IFN (500–1000 IU/ml) led to 37-fold decreased colony-forming activity of these cell and 
10-fold reduction of the number of cells expressing mesenchymal protein markers (N-cadherin, vimentin). Also, in COLO 205 cells 
treated with ACD and IFN the number of SLUG- and CD44-positive cells decreased by 92 and by 85%, respectively. Long-term cultiva-
tion of HT-29 cells in the presence of cisplatin and IFN resulted in 5-fold suppression of ERCC1 expression. The cytogenetic analysis 
has shown that the ACD, IFN and their combinations in subtoxic concentrations caused significant genotoxic effect, suppression of cell 
proliferation and accumulation of cells with micronuclei. The sensitivity of colon cancer cells to ACD in standard cytotoxic concentrations 
did not change after prolonged low-dose exposure. Conclusion: The data showed that the prolonged action of the low doses of ACD on hu-
man colon cancer cells resulted in the suppression of cell proliferation, colony-forming activity in soft agar, expression of epithelial-
mesenchymal transition-associated markers and significant cytogenetic changes.
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In clinical practice the standard chemotherapy 
of cancer patients is limited by its high toxicity and 
the development of anticancer drug (ACD) resistance. 
Therefore, it is considered important to implement 
metronomic chemotherapy regimen, in which the ACD 
are administered in low doses at short intervals [1–4]. 
The ACD doses vary in rather wide range and depend 
on the ACD, tumor type and stage etc., but such doses 
are always much lower (5–20 times) than the doses 
used in standard chemotherapy. Metronomic chemo-
therapy regimen allows reducing the level of the overall 
toxicity of chemotherapy and side effects. It is known 
that low doses of ACD had no cytostatic effect toward 
tumor cells, but retain high activity as inhibitors of neo-
angiogenesis [5]. It is believed that metronomic low-
dose regimen (MLDR) is targeted not against tumor 
cells, which are genetically unstable and form resistant 
to chemotherapy phenotypic variants, but against ge-
netically stable and highly sensitive to chemotherapy 
normal endothelial cells required for tumor growth 
[6, 7]. The authors consider following mechanisms 
of MLDR action: its antiproliferative effect against en-
dothelial cells, blockage of VEGF, inhibiting of matrix 
metalloprotei nases and tissue plasminogen activator, 
and increased endogenous thrombospondin 1 result-
ing in apoptosis of CD36-positive endothelial cells 
[8]. By our opinion, this list of MLDR mechanisms 
could be continued, because even in the absence 
of direct cytotoxic effect of ACD one could not exclude 
its effect on tumor cells by modifying their biological 
characteristics. It is logical to assume that the ACD 
as a biologically active substance will affect not only 
tumor cells through induction of cell death, but also 
through modification of their characteristics, includ-
ing the reversal of their malignancy. In particular, our 
previous studies have shown that type I interferon (IFN) 
at the doses that do not affect the growth acti vity, 
proliferative potential and viability of cells in gene ral, 
exerts long-term effects on tumor cells caused by sup-
pression of their malignant potential through inhibition 
of proteins and transcription factors associated with 
epithelial-mesenchymal transition (EMT) [9, 10]. Bio-
logical characteristics and immunophenotype of tumor 
cells to a large extent determine the rate of tumor 
growth, its drug sensiti vity, and intensity of metasta-
sis. In turn, the EMT plays a key role in tumorigenicity, 
metastatic cascade and drug resistance of tumors. 
Accordingly, the assessment of MLDR impact into bio-
logical characteristics of tumor cells and the expres-
sion of proteins involved in EMT regulation is an actual 
problem. In our previous study [3], a positive result 
of MLDR in the treatment of patients with metastatic 
colorectal cancer associated with its antiangiogenic 
therapeutic effect was demonstrated. It was shown 
that the mostly effective MLDR schemes were based 
on the use of platinum drugs and camptothecin deriva-
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tives in combination with IFN, and resulted in disease 
stabilization, a significant increase in survival period 
of patients with metastatic colorectal cancer and pro-
vided a relatively high quality of their life.
These important clinical results of MLDR use and 
new data about activity of IFN as an inhibitor of EMT 
in tumor cells were the prerequisite for the in vitro study 
of influence of IFN and ACD with different mechanisms 
of action, including derivatives of camptothecin and 
platinum drugs, on the biological characteristics and 
immunophenotypic profile of colon cancer cells. In this 
case, special attention was focused on the influence 
of ACD at the doses that corresponded to these 
in the blood of patients treated with MLDR — much 
lower than the IC50, on EMT-associated proteins, 
and consequently, on the biological and cytogenetic 
characteristics of tumor cells.
MATERIALS AND METHODS
Cell lines. Cells of human colon cancer (COLO 205, 
HT-29 cell lines) and new stable cell line from primary 
culture of ascitic fluid of the patient with colorectal 
adenocarcinoma generated by 20 passages in vitro 
(3С-Р cell line) were obtained from the Bank of Cell 
Lines of Human and Animal Tissues, R.E. Kavetsky In-
stitute of Experimental Pathology, Oncology and Radio-
biology, NAS of Ukraine (Kyiv, Ukraine). COLO 205 cells 
were maintained in RPMI-1640 medium (Sigma, USA) 
supplemented with 10% fetal bovine serum (FBS) 
(PAA, Austria) and 40 μg/ml gentamicin (Sigma, USA). 
HT-29 and 3C-P cell lines were maintained in plastic 
flasks (TPP, Italy) in DMEM with 4 mmol/l L-glutamine 
(PAA, Austria) and 10% of FBS (PAA, Austria) and 
40 μg/ml gentamicin (Sigma, USA). The cells were 
incubated at 37 °C in a humidified atmosphere with 5% 
CO2. Cells were detached with EDTA solution (Sigma, 
USA) and cultured by the standard method [11].
Modified cell sublines were obtained in our labora-
tory by treatment of COLO 205, HT-29 and 3С-Р cells 
with subtoxic doses (10–20 times lower than ІС50 es-
tablished for each culture) of cisplatin (CP), irinotecan 
(IT) and human recombinant IFN-α 2b for 30 days. The 
final concentration of drugs were as following: platinum 
drugs (cisplatin) — 0.2–0.5 μg/ml (ІС50 — 8 μg/ml), 
camptothe cin derivative (irinotecan) — 0.1–0.2 μg/ml 
(ІС50 — 2.5 μg/ml), and IFN (laferobion) — 500–
1000 IU/ml (ІС50 — 10,000 IU/ml).
Analysis of growth kinetic of tumor cells. Stu-
died cells (1•104 cells/ml) were seeded in 24-wells 
plates (TPP, Italy) in 1.5 ml of complete DMEM 
or RPMI-1640 and incubated for 8 days. Every 24 h the 
cells were detached with EDTA solution (BioTestMed, 
Ukraine) from three wells at each time point, stained 
with trypan blue solution (HyClone, USA) and counted 
in hemocytometer.
Semisolid agar colony assay. The assay was 
conducted in parallel wells of 6-well plates. Base lay-
ers of 4 ml of 0.5% agar (Difco, USA) were prepared 
on RPMI-1640 medium with 10% FBS. A 2 ml over-
layer of 0.33% agar containing studied cells (2•103) 
in DMEM medium with 10% FBS and 40 μg/ml genta-
micin was then applied and the plates were incubated 
at 37 °C in a humidified atmosphere containing 5% CO2. 
After 14 days of the incubation, the plating colonies 
were stained with 0.2% methylthiasoliletetrazolium 
solution (Sigma, USA) at 37 °C for 2 h. After that, the 
number of colonies was counted in each well using bi-
nocular magnifiers BM-51–2 (LOMO, Russia). Colony-
forming activity (CFA) of studied cells was determined 
by the formula: 
CFA = (A/B) • 100%, 
wherein A — the number of colonies per well; B — 
the number of cells planted in semisolid agar per well.
immunocytochemical assay.  Phenotypic 
changes of the studied cells after their prolonged 
treatment with ACD and IFN were determined by count-
ing the cells expressing CD44, N-cadherin, vimentin, 
β-catenin, ERCC1 and Slug. Control and modified cells 
were placed on the glass slides (cytospin samples) and 
the analysis was made by the standard method with the 
use of monoclonal antibodies against CD44 (Diagnos-
tic BioSystems, USA), N-cadherin, vimentin, β-catenin 
(ThermoScientific, USA), ERCC1 (Аbcam, USA), Slug 
(GenTex, USA). Ultra Vision LPValue Detection system 
(Thermo Scientific, USA) was used to visualize the 
reaction of antigen/ antibody. DAB Quanto (3,3-di-
aminobenzydyn) (Thermo Scientific, USA) was used 
as a chromogen. Stained preparations were analyzed 
using binocular Axiostar Plus microscope and immer-
sion oil at the magnification × 100 and photographed 
using camera Canon PowerShot G5. Expression 
of mentioned proteins was evaluated semiquantitavely 
using H-score system accounting the number and 
intensity of the stained cells. The percentage of the 
stained cells was multiplied by score number corre-
sponding to the staining intensity (0 = none, 1 = weak, 
2 = moderate, 3 = strong). The resulting score ranged 
from 0 (no stained cells) to 300 (diffuse intense stain-
ing of cells), and H-score was calculated as (percent-
age of cells stained at intensity 1×1) + (percentage 
of cells stained at intensity 2×2) + (percentage of cells 
stained at intensity 3×3) [12].
Cytogenetic analysis. Studied cells were de-
tached with EDTA solution and incubated for 40 min 
in hypotonic solution of KCl (0.54%) (Reahim, Ukraine) 
at 37 °C. After that the cells were fixed with methanol 
(Reahim, Ukraine) and acetic acid (Chemlaborreactiv, 
Ukraine) at a ratio of 3:1. The procedure of fixing was 
performed in triplicate. Cell suspension in the fixing 
solution was dripped on the cold wet glass slides and 
dried. Samples were stained with Giemsa stain (Merck, 
Germany). The cytogenetic preparations were ana-
lyzed using binocular Axiostar Plus microscope (Сarl 
Zeiss, Germany) at the magnification × 100 and pho-
tographed using camera Canon PowerShot G5 (UK). 
The following characteristics were studied: number 
of mitoses, cells with micronuclei (MN), apoptotic 
cells and cells with nuclear protrusions. These indica-
tors were counted per 1000 cells, and the results are 
expressed in per mille (‰) [13].
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Statistical analysis. Statistical analysis of the 
data was performed by the Student t-test using Sta-
tistica 6.0 program. The data are presented as M ± 
SD. Statistical significance was set at p ≤ 0.05.
RESULTS AND DISCUSSION
To investigate the impact of subtoxic doses 
of cytostatics on colorectal cancer cells, as potential 
modifiers of their malignant phenotype, we have used 
the ACD usually applied in the clinic for the treatment 
of patients with colorectal cancer — camptothecin 
derivative and a platinum drug. These drugs were 
used in mono- or combined regimes because they 
have different mechanisms of action and could exert 
a synergistic effect [14, 15].
For example, CP is a DNA crosslinker that changes 
the DNA structure and functions, inhibits its synthesis, 
thereby leading to cell death. IT is a semi-synthetic 
derivative of camptothecin that is a specific inhibitor 
of topoisomerase-1, and causes damage to the single-
stranded DNA and blocks its replication. Also, we have 
investigated the impact of the low doses of IFN on colon 
cancer cells. IFN — multifunctional cytokine, which exerts 
antiproliferative and antiangiogenic effects and is capa-
ble to modify the phenotype of tumor cells, reduce their 
tumorigenicity [9] and increase their sensitivity to ACD.
Firstly, we have studied the morphology, growth 
and immunophenotypic patterns of COLO 205 cells 
after their exposure to the abovementioned agents. 
This model was selected because of its initial biological 
chara cteristics, such as the dominance of mesenchymal 
features. Our observations showed that after addition 
of the investigated drugs or their combinations, the 
number of COLO 205 living cells did not change statisti-
cally significant compared to control cells within the first 
10 days of cultivation, but after 15 days of cultivation, the 
rate of cell growth started to decline. It should be men-
tioned that the most significant antiproliferative effect 
was observed in the cells exposed to low-dose IT (Fig. 1).
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Fig. 1. Percentage of COLO 205 living cells after their cultivation 
with subtoxic doses of ACD compared to control. *p < 0.05 com-
pared with control cells
Significant changes in the morphology of these 
cells and their adhesion to the substrate was observed 
only after 2 weeks of COLO 205 cultivation in the pre-
sence of CP, IT, and IFN. The most significant impact 
on the morphology of COLO 205 cells was observed 
in the case of treatment with IFN and CP (Fig. 2).
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Fig. 2. Morphology of live COLO 205 cells: control cells (a), cells 
treated with IFN (b) or CP (c) within 14 days, × 320
The malignancy of these cells was studied in vitro 
by semisolid agar colony assay. Our investigation has 
shown that treatment of COLO 205 cells with MLDR and 
IFN has resulted in a significant inhibition of their abi-
lity to form colonies in semisolid agar (Table 1). In this 
case, the most significant effect was caused by IT and 
complex action of these ACD and cytokine.
Thereby, the results of semisolid agar colony assay 
in vitro showed the suppression of the features of tu-
mor cell malignancy upon their exposition to subtoxic 
doses of ACD and IFN. Also, we have studied immu-
nophenotypic features of the cells, including adhesion 
and cytoskeleton proteins associated with EMT such 
as Е- and N-cadherins, CD44, β-catenin, transcription 
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factor Slug, which is directly related to the regulation 
of cell adhesion, invasion and migration, and protein 
that is responsible for drug resistance of tumor cells 
to some ACD — ERCC1 (DNA excision repair protein) 
(Table 2, Fig. 3, 4).
Table 1. CFA of COLO 205 cells after their prolonged exposure to low 
doses of ACD and IFN
Treatment CFA, %
Control 9.25 ± 0.62
IFN 7.25 ± 0.48
IT 1.66 ± 0.33**
CP 3.25 ± 0.25*
IT + CP 1.25 ± 0.25**
IT + IFN 1.00 ± 0***
CP + IFN 2.50 ± 0.29*
IT + CP + IFN 0.25 ± 0.25***
Note: The difference is statistically significant compared with control 
COLO 205 cells; *р < 0.005; **р < 0.002;***р < 0.001.
Table 2. Immunophenotypic profile of COLO 205 cells after prolonged ex-
posure to the subtoxic doses of ACD and IFN
Antigen
Drugs
Co
nt
ro
l
ІFN ІТ CP ІТ + CP
ІТ + 
ІFN
CP + 
ІFN
ІТ + 
CP + 
ІFN
Points (Н-Score)
N-cadherin 108 ± 
22
< 10 < 10 32 ± 
6*
< 10 < 10 54 ± 9 < 10
CD44 118.6± 
3.6
8.8 ± 
2.2***
105.4± 
4.8
25 ± 
1.7***
72.2 ± 
2.3 **
5.3 ± 
2.3***
12.3 ± 
2.2***
14.6 ± 
1.7***
Slug 300 < 10 < 10 194 ± 
3.2***
< 10 < 10 < 10 < 10
Note: The difference is statistically significant compared with control 
COLO 205 cells; *р < 0.05; **р < 0.002, ***р < 0.001.
As it was recently accepted, these proteins de-
termine the EMT status of cells and participate in the 
formation of their invasive-metastatic phenotype. For 
exa mple, N-cadherin is a Ca-dependent transmem-
brane protein of classical cadherin family, regulating 
cell adhesion, but in contrast to E-cadherin, it promotes 
the separation of cells from the original tumor mass, 
their migration, and initiates the metastatic cascade. 
The other adhesion molecules, CD44 antigen also has 
direct relevance to the invasive and migratory activity 
of tumor cells and is used as a marker of progression 
and metastasis in many cancer types, including breast 
cancer cells with the phenotype of CD44+ CD24− 
considered as “cancer stem cells” [16]. A potential 
regulator of cell adhesion and migration, transcription 
factor Slug plays an important role in the physiological 
(embryogenesis) and pathological (malignancy) EMT 
of cells and is a suppressor of E-cadherin promoter 
through its inhibition [17]. It is known that an increased 
expression of Slug provides tumor cells with the mesen-
chymal phenotype and high metastatic potential [18]. 
To study the effects of subtoxic doses of ACD on tumor 
cell phenotype, expression of abovementioned proteins 
was assessed in COLO 205, HT-29, and 3C-P cells.
The results of the study of immunophenotypical 
characteristics of the cells are presented in Tables 2, 3. 
As it is shown in Table 2, the prolonged exposure of the 
COLO 205 cells to IT and IFN in monoregimen or in com-
binations resulted in significant reduction of the number 
of N-cadherin-positive cells; the action of CP also de-
creased the expression of this antigen but at the lower 
level. Regarding expression of CD44, stem cell marker, 
the lowest effect was observed in the case of low-dose 
IT: the expression of CD44 decreased by 11.1%, while 
the most significant effect was registered in the case 
of combined action of IFN and the cytostatics. The 
most interesting observation was almost complete 
inhibition the Slug expression in COLO 205 cells under 
the influence of subtoxic doses of the studied drugs 
used either in monoregimen or in combination; only 
the influence of CP did not reduce significantly number 
of Slug-positive cells (35.4%).
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Fig. 3. Immunocytochemical analysis of ERCC1 expression 
in COLO 205 cells after prolonged (30 days) exposure to the 
subtoxic doses of ACD. *p < 0.05 compared with control cells
Another studied antigen was ERCC1, a protein that 
takes part in DNA repair. According to the literature, 
an increased expression of this protein in colon cancer 
cells is associated with their high resistance to plati-
num-based chemotherapy [19, 20] and is the basis for 
the indication of IT (camptothecin) to such patients. 
As we have shown (see Fig. 3, 4), the use of IFN and 
its combination with IT and CP resulted in the almost 
complete disappearance of ERCC1-positive cells. The 
action of CP and CP combined with IFN led to significant 
decrease the number of ERCC1-positive cells, while 
the prolonged action of IT and CP combination resulted 
in an increased number of ERCC1-positive cells.
The changes of immunophenotypic features of HT-
29 cells with predominantly epithelial characteristics 
are shown in Table 3. Immunocytochemical analysis 
of ERCC1 expression in HT-29 cells revealed signifi-
cantly increased the number of ERCC1-positive cells 
Table 3. Immunophenotypic profile of HT-29 cells after prolonged exposure to the subtoxic doses of ACD and IFN
Antigen
Drugs
Control ІFN ІТ CP ІТ + CP ІТ + ІFN CP + ІFN ІТ + CP + ІFN
Points (Н-Score)
CD44 120.0 ± 11.6 110.0 ± 4.0 255.0 ± 16.5** 205.0 ± 9.0* 225.0 ± 11.0** 230.0 ± 17.5* 210.0 ± 8.4** 198.0 ± 2.0**
Slug (localization 
in cytoplasm)
34.0 ± 1.6 < 10 21.0 ± 7.0 134.0 ± 8.6 *** 174.0 ± 11.0*** < 10 < 10 62.0 ± 4.0**
Note: The difference is statistically significant compared with control HT-29 cells; *р < 0.02; **р < 0.01; ***р < 0.002.
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Fig. 4. Immunocytochemical analysis of ERCC1 expression in COLO 205 cells after prolonged (30 days) exposure to the subtoxic 
doses of ACD. a: control cells; b: + IFN; c: + IT; d: IT + IFN; e: + CP; f: CP + IFN; g: IT + CP; h: IT + CP + IFN (× 1000)
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exposed to IT or IT + CP (Fig. 5). The same trend was ob-
served in COLO 205 cells, although in the case of com-
bined action of IT with IFN a significant reduction in the 
number of ERCC1-positive cells was noted, whereas 
in HT-29 cells such effect wasn’t observed. A significant 
decrease of ERCC1-positive cells was observed only 
if IFN was used in monoregimen or in combination with 
CP. Expression of E-cadherin did not differ significantly 
between the control cells and cells treated with ACD 
(approximately 180–220 points by the H-Score system). 
We suppose that this fact evidences on a higher stability 
of cells with the dominance of epithelial characteristics 
vs these with mesenchymal characteristics.
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Fig. 5. Immunocytochemical analysis of ERCC1 expression 
in HT-29 cells after prolonged (30 days) exposure to the subtoxic 
doses of ACD. *p < 0.05 compared with control cells
The study of CD44 expression in HT-29 cells has 
shown significantly increased number of CD44-posi-
tive cells treated with CP and IT, but not IFN (Table 3) 
compared to the cells of mesenchymal phenotype 
(COLO 205) in which the number of CD44-positive 
significantly decreased after exposure to CP and ACD 
combined with IFN (Table 2).
The analysis revealed the location of transcription 
factor Slug only in the cytoplasm of HT-29 cells and 
in control cells — at a low level (since this factor 
is chara cteristic of mesenchymal cells), while after 
the action of CP the number of Slug-positive cells 
significantly increased. The additional effect of IFN 
significantly reduced the number of Slug express-
ing cells. A similar trend was observed in the study 
of COLO 205 cells: the highest number of cells with 
Slug expression was observed after their exposure 
to CP (although lower than in control cells), which was 
significantly reduced by the additional effect of IFN 
(Table 2). These facts require further investigations 
of crosstalk between IFN system and reparation and 
adhesion proteins, as far as they indicate the capability 
of IFN to exert antitumor action dependent on the EMT 
status of tumor cells.
Also, we have investigated the influence of ACD 
on a newly established cell line 3C-P derived from 
ascitic fluid of the patient with colon cancer. Its growth 
kinetics after more than 20 passages in vitro is shown 
in Fig. 6. The cells of 3C-P line are characterized 
by quick proliferation with a maximal growth density 
on day 4 and then a significant reduction in the number 
of living cells was observed.
3C-P cells were exposed to low-dose IFN, CP, 
IT and then immunocytochemical analysis of the 
markers associated with EMT has been conducted 
(Table 4). This investigation was of special impor-
tance because these cells underwent a small number 
of doublings in vitro, yet are heterogeneous and did 
not accumulate a large number of mutations. Interest-
ingly, in the case of IFN combined with IT in subtoxic 
concentrations total cell death was registered, but not 
if these agents were used in monoregimen.
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Fig. 6. Kinetics of growth (number of live cells) of the newly 
established 3C-Р cell line
Similarly, to the cells with a mesenchymal pheno-
type, COLO 205, a trend for reduction of the number 
of CD44-positive cells after exposure of 3C-P to IFN 
was observed, while other ACD had no effect on the 
CD44 expression. The number of β-catenin-positive 
cells significantly increased after exposure of 3C-P cells 
to IFN (and in the case of its combination with CP) and 
IT, while CP did not influence the marker expression 
(Table 4). Significantly decreased number of vimentin-
positive cells after the action of IFN was registered, 
while the action of IT resulted in increased number 
of cells expressing this antigen.
Таble 4. Immunophenotypic profile of 3C-P cells after prolonged exposure 
to the subtoxic doses of ACD and IFN
Аntigen
Drugs
Control CP ІT ІFN CP + ІFN
Points (H-Score)
СD44 19 4  ±  6 210 ± 15 192 ± 8 124 ± 10** 215 ± 22
β-catenin 32 ± 11 24 ± 2 180 ± 15*** 140 ± 4*** 125 ± 15*
Vimentin 180 ± 11 132 ± 3* 262 ± 7** 80 ± 14* 112 ± 4*
Note: The difference vs control 3C-P cells is statistically significant; *р < 0.02; 
**р < 0.01; ***р < 0.005.
Thus, immunocytochemical analysis showed that 
in 3C-P cells IFN inhibited manifestation of the me-
senchymal phenotype, while IT and CP had a multidi-
rectional impact on the expression of EMT markers.
Next, we analyzed whether long exposure of the 
cells to low-dose ACD in vitro affected their drug resis-
tance. For this purpose, we compared the IC50 values 
of colon cancer cells to standard (high) doses ACD 
before and after long-term low-dose treatment and 
revealed that IC50 values did not differ significantly 
in all studied cell lines (data not shown).
At last, the cytogenetic analysis of COLO 205 cells 
(number of mitoses, a number of cells with MN, apop-
totic cells and cells with nuclear protrusions) has been 
conducted (Fig. 7). As markers of genotoxic events 
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and chromosomal instability, there are used counting 
of cells with MN and other nuclear abnormalities, such 
as nucleoplasmic bridges, nuclear buds, nuclear “tails”, 
dumbbell nucleus [21]. MN are formed mainly from acen-
tric chromosomal fragments or individual chromosomes 
that are not included into the daughter nuclei during 
telophase [22]. Since MN and various nuclear abnormali-
ties are the results of clastogenic and aneugenic events, 
the counting these abnormalities in cells is a convenient 
method for evaluation of cytogenetic instability in vitro 
after exposure to different chemical agents [23–27].
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Fig. 7. Cytogenetic characteristics of COLO 205 cell line: a) mi-
tosis, b) cell with MN, c) apoptosis, d) nuclear protrusion
In our study, it was found that control COLO 205 cells 
have a relatively high cytogenetic stabi lity — the num-
ber of cells with MN was 1‰, cells with protrusions — 
9‰, relatively high proliferative activity of cells with 
mitosis frequency 14 ‰ (Table 5). After cultivations 
with CP, IT, and IFN at subtoxic doses, the significant 
increase of the COLO 205 cells with MN and inhibition 
of mitosis (р < 0.05) as well as a trend for accumula-
tion of the cells with nuclear abnormalities were found 
(Table 5).
Table 5. Cytogenetic characteristics of COLO 205 cells after their pro-
longed exposure to subtoxic doses of ACD and IFN
Cytogenetic  
characteristics
Drugs
Control CP ІТ ІFN
Frequency of cells (‰)
Cells with MN 1.33 ± 1.5 7.00 ± 1.7* 7.00 ± 1.0* 7.00 ± 1.0*
Mitosis 13.67 ± 1.5 4.33 ± 1.5* 6.67 ± 1.1* 2.67 ± 0.6*
Apoptosis 8.67 ± 1.5 9.00 ± 1.0 7.67 ± 1.5 10.33 ± 0.6
Nuclear protrusions 9.33 ± 1.5 12.33 ± 1.1 9.67 ± 1.1 10.67 ± 1.5
Note: The difference is statistically significant compared with control 
COLO 205 cells; *р < 0.05; **р < 0.01.
Thus, such exposure on the cells resulted in geno-
toxic events. The IT + IFN combination had the most 
significant genotoxic effect in COLO 205 cells causing 
the decrease of mitotic activity (р < 0,05) and accumula-
tion of cells with MN (p < 0.001) which is almost 40 times 
higher than the value in the control cells (Table 6). 
The combination of IT + CP caused lower cytogenetic 
disorders possibly due to the induction of apoptosis, 
which is 2 times higher than in control cells (p < 0.001), 
however, led to significant genotoxic effect, in par-
ticular, decrease of proliferative activity (p < 0.05) and 
high frequency of cells with MN (p < 0.05). The com-
bination of IFN + CP had the lowest genotoxicity of all 
drug combinations (Table 6). So, prolonged treatment 
of COLO 205 cells with ACD in subtoxic doses resulted 
in genotoxic effects, i.e. reduction of cell proliferation 
and accumulation of cells with MN.
Table 6. Cytogenetic characteristics in COLO 205 cell line after prolonged 
exposure to subtoxic doses of ACD, their combinations and IFN
Drugs
Cytogenetic 
characteris-
tics
Control CP + IFN ІТ + ІFN CP + ІТ CP + ІТ + ІFN
Frequency of cells (‰)
Cells with MN 1.33 ± 1.5 6.00 ± 0.00* 38.67 ± 2.5** 14.67 ± 2.0* 12.00 ± 1.7*
Mitosis 13.67 ± 1.5 3.5 ± 0.41* 3.33 ± 0.6* 3.33 ± 0.6* 3.33 ± 1.1*
Apoptosis 8.67 ± 1.5 9.00 ± 0.82 8.00 ± 1.0 18.67 ± 1.5** 9.67 ± 0.67
Nuclear pro-
trusions 9.33 ± 1.5 10.50 ± 0.41 8.00 ± 1.1 11.00 ± 1.0 7.00 ± 1.0
Note: The difference is statistically significant compared with control 
COLO 205 cells; *р < 0.05; **р < 0.01.
CONCLUSION
The data showed that the direct prolonged ac-
tion of the low doses of ACD on human colon cancer 
cells resulted in the suppression of cell proliferation, 
colony-forming activity in soft agar, expression of EMT-
associated markers and significant cytogenetic 
changes. The sensitivity of colon cancer cells to ACD 
in standard cytotoxic concentrations did not change 
after prolonged low-dose exposure.
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